Home Use of Mini-Dose Glucagon As a Novel Treatment for Hypoglycemia Following Repeated, Prolonged Fasts in Type 1 Diabetes During Ramadan

• DOI: 10.2337/figshare.18857882.v1
• Publication Date: 2022-03-03T15:07:23Z
• Authors: Metab A Algeffari; Sufyan Hussain; Turki A Almogbel; Mansour S Alsharidah; Habibah A Alghadouni; Farid M Mahmood
• Keywords: Crossover study

Objective: <br>We determined the efficacy of self-administered subcutaneous mini-dose glucagon (MDG) to treat fasting-induced hypoglycemia in type 1 diabetes (T1D). <br>Research Design and Methods <br>4-week randomized, controlled crossover trial (2-week MDG or 2-week oral glucose tablets (OG, control)) involving 17 adults with T1D during Ramadan. <br>Results <br>As compared OG, demonstrated a significant higher change blood from baseline 30 minutes (∆t30, P<0.001) hour (∆t60, P=0.02). The was preserved following ≥8 hours fasting significantly ∆t30 (P=0.01). Over entire two-week, period had increased time 70-180 mg/dL (P=0.009) less time<70 (P=0.04). use resulted completion fasts as OG (P<0.001). <br>Conclusions <br>MDG administration is an effective alternative for prevention treatment hypoglycemia, offering improved glycemic control promoting successful prolonged fasts.